Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)

Trial Profile

Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Idalopirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 10 Nov 2016 Planned primary completion date changed from Dec 2016 to Sep 2016.
    • 10 Nov 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 17 Oct 2016 Status changed from recruiting to discontinued based on new efficacy data from another study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top